Leniolisib does not currently have an active patent in the United States [1].
When does the leniolisib patent expire?
As there is no active patent for leniolisib in the US, there is no patent expiration date to report for this drug in that region [1].
Are there other forms of protection for leniolisib?
While leniolisib does not have an active US patent, other forms of market exclusivity might exist. These can include data exclusivity periods, which prevent generic manufacturers from relying on the innovator's clinical trial data for a certain number of years, even if a patent has expired or never existed [2]. Regulatory approvals can also confer periods of exclusivity.
How does leniolisib work?
Leniolisib is a selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor [3]. PI3Kδ is involved in the survival and proliferation of various immune cells, including B cells [3]. By inhibiting PI3Kδ, leniolisib can reduce the activity of these cells, which is beneficial in certain immune dysregulation disorders.
What is leniolisib used for?
Leniolisib is indicated for the treatment of activated PI3K-delta syndrome (APDS) [3]. APDS is a rare primary immunodeficiency characterized by the overactivity of the PI3Kδ enzyme in immune cells, leading to recurrent infections, lymphoproliferation, and immune dysregulation [3].
How is leniolisib administered?
Leniolisib is administered orally [3].
What are the potential side effects of leniolisib?
Common side effects of leniolisib may include diarrhea, nausea, vomiting, and upper respiratory tract infections [3]. Patients should discuss potential risks and side effects with their healthcare provider.
Can generic versions of leniolisib be developed?
The development of generic versions of leniolisib would depend on patent status and any other applicable exclusivity periods. Without an active patent, the path to generic development might be more straightforward, provided regulatory hurdles are met [2].
Who developed leniolisib?
Leniolisib was developed by Viatris [4].
What is the difference between leniolisib and other PI3K inhibitors?
Leniolisib is a selective inhibitor of the PI3Kδ isoform [3]. Other PI3K inhibitors may target different isoforms of PI3K or be non-selective, which can lead to different efficacy and side effect profiles [3]. The selectivity of leniolisib for PI3Kδ is key to its mechanism in treating APDS.
Where can I find more information on drug patents?
Information on drug patents, including their status and expiration dates, can be found on DrugPatentWatch.com [1].
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.drugpatentwatch.com/blog/understanding-drug-exclusivity-periods
[3] https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217322s000lbl.pdf
[4] https://www.viatriks.com/